Danaher: stocks, financial statements

Dividends News

Danaher Corp. operates as a medical company, which designs, manufactures, and markets professional, medical, industrial and commercial products and services. It operates through the following five segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions. The Life Sciences segment offers a range of research tools that scientists use to study the basic building blocks of life, including genes, proteins, metabolites and cells, in order to understand the causes of disease, identify new therapies and test new drugs and vaccines. The Diagnostics segment comprises of analytical instruments, reagents, consumables, software, and services that hospitals, physician's offices, reference laboratories, and other critical care settings use to diagnose disease and make treatment decisions. The Dental segment develops products and services that are used to diagnose, treat and prevent disease and ailments of the teeth, gums, and supporting bones; as well as to improve the aesthetics of the human smile. The Environmental & Applied Solution segment offers products and services that help protect important resources and keep global food and water supplies safe. The company was founded by Steven M. Rales and Mitchell P. Rales in 1969 and is headquartered in Washington, DC.

  • DHR Ticker
  • NYSE Exchange
  • 71,000 Employees
11 rated

Financial statements — Danaher

The information is not 100% up-to-date. There may be errors or missing information. Some information is often missing, and, although there are almost no errors, I can't rule them out. Right now, I'm looking for a supplier of high-quality information, but so far what I'm finding is expensive (about $2000 a year). You can help my project here.
20 ← 16 2020 2019 2018 2017 2016
Total Revenue
22B 18B 20B 18B 17B
Cost Of Revenue
9.8B 7.9B 8.8B 8.1B 7.5B
Gross Profit
12B 10B 11B 10B 9.3B
Research and Development
1.3B 1.1B 1.2B 1.1B 980M
Selling General and Admin
6.9B 5.6B 6.5B 6B 5.6B
Operating Expense
18B 15B 16B 15B 14B
Operating Income
4.2B 3.3B 3.4B 3B 2.8B
Other Income Expense Net
0 0 0 0 0
4.2B 3.3B 3.4B 3B 2.8B
Interest Income
200M -30M 150M 160M 180M
Pretax Income
4.5B 3.3B 3.3B 2.9B 2.6B
Income Tax
850M 870M 640M 470M 460M
Minority Interest
0 0 0 0 0
Net Income
3.5B 2.9B 2.7B 2.5B 2.6B
Net Income Basic
3.5B 2.9B 2.7B 2.5B 2.6B
20 ← 16 2020 2019 2018 2017 2016
Current cash
6B 20B 790M 630M 960M
Short term investments
1.4B 860M 910M 860M 810M
4B 3.2B 3.5B 3.5B 3.2B
2.3B 1.6B 1.9B 1.8B 1.7B
Other current assets
1.4B 860M 910M 860M 810M
Current assets
14B 26B 7.1B 6.9B 6.7B
Long term investments
62B 36B 41B 40B 39B
Property plant equipment
3.3B 2.3B 2.5B 2.5B 2.4B
35B 23B 26B 25B 24B
Intangible assets
21B 9.7B 12B 12B 12B
Other assets
2.2B 1.6B 460M 490M 460M
Total assets
76B 62B 48B 47B 45B
Accounts payable
2B 1.5B 1.7B 1.5B 1.5B
Current long term debt
11M 210M 52M 190M 2.6B
Other current liabilities
5.3B 3.2B 3.1B 3.1B 2.8B
Total current liabilities
7.4B 4.9B 4.8B 4.8B 6.9B
Long term debt
21B 22B 9.7B 10B 9.7B
Other liabilities
7B 4.7B 5.1B 5.2B 5.7B
Minority Interest
11M 11M 12M 9.6M 74M
Total Liabilities
36B 32B 20B 20B 22B
Common stock
710M 720M 700M 700M 690M
Retained earning
27B 24B 25B 23B 21B
Treasury stock
0 0 0 0 0
Capital surplus
Shareholder equity
40B 30B 28B 26B 23B
Net tangible assets
-20B -3.8B -9.4B -10B -13B
20 ← 16 2020 2019 2018 2017 2016
Net Income
3.5B 2.9B 2.7B 2.5B 2.6B
1.8B 1.2B 1.3B 1.2B 1.1B
Changes in receivables
850M -300M -32M 340M -780M
Changes in inventories
660M -280M 69M 130M -390M
Cash change
-14B 19B 160M -330M 170M
Cash flow
6.2B 4B 4B 3.5B 3.5B
Capital expenditures
-790M -640M -660M -620M -590M
Investing activity other
Total investing cash flows
-21B -1.2B -2.9B -840M -5.2B
Dividends paid
Net borrowings
14B 950M 8B 9B 10B
Other financing cash flows
Cash flow financing
1B 16B -800M -3.1B 2B
Exchange rate effect